curasan Gains CE Mark for Spinevisc Hyaluronic Acid

By Julie A. Vetalice

curasan is launching Spinevisc® hyaluronic acid (HA) for the treatment of facet joint arthrosis.

Spinevisc will allow the company to address new target customer groups such as neuroradiologists and interventional pain therapists, as well as spine surgeons.

Other HA-based products from curasan include Curavisc for the treatment of arthritic joints ex-U.S. and CERASORB bone replacement material.

Source: curasan AG

Product Labels: Synthetic Bone Graft

Tags: CE Mark, Regulatory